肝疾病中炎症衰老机制研究进展  

Advances in inflammaging in liver disease

作　　者：徐燕萍 陈璐祎 刘玮丽[1] 陈丽英[1] XU Yanping;CHEN Luyi;LIU Weili;CHEN Liying(Department of General Practice,Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou 310016,China)

机构地区：[1]浙江大学医学院附属邵逸夫医院全科医学科,浙江杭州310016

出　　处：《浙江大学学报(医学版)》2025年第1期90-98,共9页Journal of Zhejiang University(Medical Sciences)

基　　金：浙江省医共体建设发展齐鲁研究项目(2024ZHA-QL206)。

摘　　要：肝疾病中的炎症衰老作用机制和干预措施是当前研究的热点。炎症衰老是一种与慢性炎症相关的细胞功能衰退过程,广泛参与肝疾病的发生发展。对于病毒性肝炎,炎症衰老的机制主要涉及氧化应激、细胞凋亡和坏死以及肠道菌群失调。非酒精性脂肪性肝病中的炎症衰老机制较为复杂,涉及胰岛素抵抗和脂肪沉积、脂质代谢紊乱、肠道菌群失调以及NAD^(+)代谢异常。肝脏肿瘤中的炎症衰老则表现为肿瘤抑制机制的减弱、肝脏微环境的重塑、代谢重编程以及免疫逃逸机制的强化。目前,针对炎症衰老的治疗策略正在逐步发展,抗氧化治疗、改善代谢紊乱以及免疫疗法等成为肝疾病干预的重要手段。本文重点探讨炎症衰老在肝疾病中的作用机制,旨在为肝疾病的预防和治疗提供依据。Inflammaging is a process of cellular dysfunction associated with chronic inflammation,which plays a significant role in the onset and progression of liver diseases.Research on its mechanisms has become a hotspot.In viral hepatitis,inflammaging primarily involve oxidative stress,cell apoptosis and necrosis,as well as gut microbiota dysbiosis.In non-alcoholic fatty liver disease,inflammaging is more complex,involving insulin resistance,fat deposition,lipid metabolism disorders,gut microbiota dysbiosis,and abnormalities in NAD^(+)metabolism.In liver tumors,inflammaging is characterized by weakening of tumor suppressive mechanisms,remodeling of the liver microenvironment,metabolic reprogramming,and enhanced immune evasion.Therapeutic strategies targeting inflammaging have been developing recently,and antioxidant therapy,metabolic disorder improvement,and immunotherapy are emerging as important interventions for liver diseases.This review focuses on the mechanisms of inflammaging in liver diseases,aiming to provide novel insights for the prevention and treatment of liver diseases.

关 键 词：肝疾病 炎症衰老 作用机制 干预 综述 

分 类 号：R592[医药卫生—老年医学]